Printer Friendly

Examine the Most Effective Strategies Employed by Pharmaceutical Companies in their Effort to Ward off the Threat of Generics Competition.

DUBLIN, Ireland -- Research and Markets ( ) has announced the addition of the Decision Resources, Inc. report: Generics Erosion Patterns in the U.S. Market to their offering.

With an estimated $51 billion of branded drugs coming off patent between 2006 and 2011, both U.S. government insurance plans and private, third-party payers will promote increased use of generics in the future. In a data-rich report that employs analyses of 34 branded drugs facing generics competition between January 2002 and December 2006, we highlight the most effective strategies employed by pharmaceutical companies in their effort to ward off the threat of generics competition.

Get the Answers You Need to Shape Your Strategy:

-Several factors determine how quickly a branded product loses market share. Which of these factors is particularly likely to lead to big paydays for generics manufacturers? Under what circumstances can the effects of this critical factor be muted?

-After Zithromax lost patent protection in the United States, Pfizer entered the generics market for Zithromax through its own generics subsidiary. How successfully did Pfizer's subsidiary fend off erosion of prescription share for Zithromax? What lessons can other drug companies take away from Pfizer's strategy?

-Merck employed an unusual pricing strategy in order to retain its market share for Zocor, after generics entered the market for the branded product. How successful was Merck in delaying erosion of Zocor's market share?

-Oral solids typically experience generics erosion at a different rate than other drug formulations (oral liquids, nasal products, and patches). What factors account for this difference?


-Methodology: thirteen figures and two tables delineating the data of generics erosion for 34 drugs between 2002 and 2006.

-Patterns of generics erosion: rates of erosion for oral solids, oral liquids, and injectables; factors determining rates of erosion; branded products grouped by their erosion rates.

-Exceptions to traditional generics erosion: drugs that did not follow traditional patterns of erosion.

-Outlook: Data from the Centers for Medicare & Medicaid Services (CMS); pending U.S. legislation.

Topics Covered

Executive Summary

Strategic Considerations

Stakeholder Implications



Factors Influencing Generics Erosion

Exceptions to Traditional Generics Erosion Patterns

Patterns of Generics Erosion by Formulation

Oral Solids

Group 1

Group 2

Group 3

Oral Liquids and Other Formulations (Nasal, Ophthalmic Liquids, Patches/Discs)


Other Findings

Comparison of Average Oral Solid Generics Erosion

Market Influence of Generics Manufacturers

Price As a Factor

Will These Patterns Continue?


1. Drugs and Formualtions Examined in this Report

2. Defi nitions and Parameters of Drug Groupings in this Report


1. Generics Erosion for Selected Products, 2002-2006: Oral Solids, Group 1

2. Generics Erosion for Selected Products, 2002-2006: Oral Solids, Group 2

3. Generics Erosion for Selected Products, 2002-2006: Oral Solids, Group 3

4. Generics Erosion for Selected Products, 2002-2006: Oral Liquids

5. Generics Erosion for Selected Products, 2002-2006: Other Formulations

6. Comparison of Average Generics Erosion (by Formulation) for Five Drugs

7. Generics Erosion for Selected Products, 2002-2006: Injectables/IVs

8. Average Generics Erosion Rates of Oral Solids, 2002-2006

9. Estimated Average Number of Generics Competitors by Formulation

10. The Effect of Generics Manufacturers on Brand Market Share Volume

11. How Brand Manufacturers Can Maintain Total Prescription Share Through Generics

Subsidiaries: Zithromax

12. How Brand Manufacturers Can Maintain Total Prescription Share Through Generics

Subsidiaries: Lotensin

13. How Brand Manufacturers Can Maintain Total Prescription Share Through Generics

Subsidiaries: Celexa

Companies Mentioned

- Accupril - Agrylin - Axid - Biaxin - Celexa - Cipro - Difl ucan - Duragesic - Effexor - Flonase - Floxin/Occufl ox - Glucophage XR - Glucotrol XL - Glucovance - Lotensin - Metaglip - Mobic - Monopril - Novantrone - Paraplatin - Paxil - Pravachol - Proscar - Retrovir - Rocephin - Romazicon - Tambocor - Ultram - Zaditor - Zestril/Prinivil - Zithromax - Zocor - Zofran - Zoloft

For more information visit
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:May 4, 2007
Previous Article:Identify the Problems That Arise from Uncontrolled and Unmanaged Spreadsheets.
Next Article:Revenues in the Wood Television, Radio, and Sewing Machine Cabinet Manufacturing Industry Reached Approximately $430,000,000.

Related Articles
Pricing, patent loss and the market for pharmaceuticals.
Rx for pharmaceuticals.
The World's Leading Pharmaceutical Companies Face Difficult Times Due to the Generics Erosion.
Generic Growth Opportunities are Significant, with an Estimated $100bn Worth of Branded Pharmaceutical Products to go off Patent by 2010, of which...
U.S. Employers' Plans for Future Restrictions on Retiree Medical Benefits.
Future Growth Opportunities in Generics: The Impact of Consolidation on Market and Competitive Dynamics.
What were 2006's Developments on the Generics Front Line? What Strategies Are Innovator Companies Employing to Ward off Generics Competition? - 2006...
Independent Study Confirms Authorized Generic Pharmaceuticals Reduce Prices Without Discouraging the Marketing of Other Generic Drugs.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters